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1. Introduction
The treatment of brain tumors remains a challenge for modern medicine and care. Therapy for
these patients is often complicated by site accessibility and the risk of damage to surrounding
tissue. The ability of chemotherapies to cross the blood brain barrier has also limited their use
as compared with surgical resections and radiation therapy. (Groothuis, 2000) For these
reasons, malignant gliomas of the central nervous system (CNS) have a poor prognosis. In fact,
the majority of patients with high grade gliomas (glioblastomas) will die within the first couple
of years after the diagnosis.(McLendon, 2003) The 5 year survival rate for these patients with
glioblastoma is less than 4% with the majority of deaths in the first two years post-diagnosis.
( Grossman, 2004; CBTRUS, 2012) This devastating impact has been the impetus behind much
of the research that is ongoing into effective therapies to combat these tumors. Over the years
many therapies have been studied, but in recent times the increased investigation into specific
molecular pathways has led to targeting specific tumor expression patterns and cellular
attributes. The enhanced understanding of cell division, including aspects of DNA replication
are now being used to target tumor replication and treat many cancers from various tissues.
In this fashion, tumors of the CNS should be more specifically targeted so that damage to the
surrounding normal tissue is minimized.
2. Epidemiology
Even after treatment, the median survival after the primary diagnosis remains poor. Many
multimodal treatment approaches are considered, but few patients have been reported to have
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long term survival greater than three years. In a recent study, analysis of 34,664 patients,
diagnosed with GBM over the age of 20 from 1972-2008 in the Surveillance, Epidemiology, and
End Results (SEER) NCI database, evaluated specific prognostic factors known to influence
survival in these patients. (Thumma, 2012) This analysis included racial/ethnic characteristics
in the description of specific subpopulations and found that Asian/Pacific Islanders had a
better survival compared to the white population (P<0.001). Patients diagnosed with GBM
during the years of 2000 to 2008 had a superior survival rate when compared with earlier
decades (P<0.001). Statistically significant improvements in overall survival were also found
for patients who received surgical resections, and adjuvant radiation treatment versus no
radiation (P values <0.001). Young age was also found to be highly predictive of improved
overall survival rates when separated into age groups as well as when studied as a continuous
variable. (Thumma, 2012) Thus, there are subpopulations with varied genomic and environ‐
mental attributes that may affect survival of CNS tumors. Although these studies did not
specifically identify the critical factors that dictate these differences, future studies may
capitalize on differences that enhance efficacy.
Despite aggressive therapy for malignant gliomas, recurrence rate is quite high and the
prognosis for most patients is extremely poor. The standard approach for high grade gliomas
is radiation therapy combined with temozolomide. (Stupp, 2005) Temozolomide added to
cranial radiation therapy improved Two year survival to 26.5% vs 10.4% to radiation therapy
alone. Toxicity of temozolomide and radiation therapy was minimal. Despite the improved
two-year survival with the addition of temozolomide to standard radiation therapy, the vast
majority of patients progress and die of their disease. Thus, more effective drugs and ap‐
proaches are definitely needed. Newer drugs being investigated include topoisomerase I
inhibitors. This chapter will review topoisomerase I inhibitors in the treatment of malignant
gliomas. Novel approaches using this class of compounds will also be discussed.
3. Current therapies
The DNA topoisomerases are a family of important enzymes involved in different stages of
the cell cycle. They are essential nuclear enzymes important in DNA topology, repair, and
replication by breaking and rejoining of the DNA double helix. The breakage that they induce
in essence unwinds the DNA structure and releases the molecule from its wound configura‐
tion. In this configuration, DNA replication as well as transcription can occur in the cell
nucleus. Two significant topoisomerase molecules are named topoisomerase I and topoiso‐
merase II. Although these molecules are in the same family, they work in different steps to
bind and cause the eventual unwinding of the helical DNA structure. Topoisomerase I is a
monomeric protein that induces single stranded breaks in DNA, one strand at a time.(Redinbo,
1998) Topoisomerase II brings about double stranded breaks in DNA since it is a dimer in
which each homologous monomer can cleave a strand of DNA.(Wang, 1996) These differences
have lead to the development of specific inhibitors to these topoisomerase enzymes. Since these
inhibitors actually damage DNA, they are sometimes referred to as poisons in the literature.
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4. Topotecan
Topotecan (TPT) is an analogue of camptothecin, an FDA approved chemotherapy for many
types of cancer.(Bookman, 1998; tenBukkel, 2004) TPT is water soluble, and inhibits an essential
role of topoisomerase I, depleting it in tumor cells and resulting in DNA strand breaks that are
not utilized or repaired.(Yamashita, 2007) Cells are then stopped in the G2 phase of the cell
cycle, and the progression of replication does not occur eventually leading to programmed cell
death through apoptotic processes. In subcutaneous xenograft models and in vitro, TPT
therapy has shown significant activity against glioblastoma (GBM) which is the most common
and malignant type of primary brain tumor.(Ciusani, 2005; Rapisarda, 2004) Topotecan
treatment showed some efficacy in preclinical studies, and TPT was found to be distributed
in the cerebrospinal fluid after systemic administration, leading to the initiation of clinical trials
evaluating the efficacy of TPT monotherapy on patients with GBM. (Ciusani, 2005; Baker,
1996) Data from phase II clinical trials with TPT treatment of both newly diagnosed and
recurrent GBM revealed modest tumor responses. It is proposed that the lack of efficacy in
treatment may be due to rapid clearance of TPT from the CSF, and rapid inactivation in plasma.
(Mi, 1995) Both of these processes provide a survival advantage to the tumors since drug
concentrations may not be significant around the tumor site. In order to address this and other
mechanisms, the approach to TPT therapy has changed from monotherapy to use in combi‐
nation with different agents targeting alternate pathways.(MacDonald,1996; Blaney,1996;
Reveiz,2012) These combinations may vary in the sequence of drug delivery or may be
simultaneous depending on the protocol used.
Topotecan is being studied as a component of combination therapies in primary brain tumors
as well as in the efficacy it may have in the treatment of brain metastases. In one recent large
scale literature review, approximately 10% to 18% of patients presented with brain metastases
(BM) at the time of initial diagnosis of small cell lung cancer (SCLC), and an additional 40% to
50% will develop brain metastases during the course of their disease. To evaluate the effec‐
tiveness and toxicity of systemic chemotherapy for the treatment of these types of brain
metastases from SCLC, the large scale systematic literature review was conducted for publi‐
cations up to July 2011.(Reveiz,2012) The literature searched included randomized controlled
trials comparing systemic chemotherapy (single agent or combination chemotherapy) vs
another chemotherapy regimen, palliative care, whole brain radiotherapy or any combination
of these interventions for the treatment of brain metastases as the sole site of progression.
(Reveiz,2012) After this extensive search, no significant differences for overall survival (OS)
were reported from randomized controlled trials with whole brain radiation therapy, and no
significant difference was found between those treated with topotecan and those not treated
with topotecan. Hence the treatment efficacy was not established in that review. A second trial
found that patients receiving teponoside plus whole brain radiotherapy had a higher complete
response rate than those receiving only the topoisomerase inhibitor. Hence, available evidence
is insufficient to judge the effectiveness and safety of chemotherapy for the treatment of brain
metastasis from small cell lung cancer. This may depend on the characteristics of the primary
tumor and the activated mechanisms of metastasis. Future research may better address the
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different combination therapies as well as monotherapies in head to head comparisons and
trials in populations with primary tumors and metastatic tumors.
Liposomes are microscopic phospholipid particles with a bilayer membrane structure, and are
used to encapsulate various anticancer drugs.(Allen, 2004; Drummond,1999,2005) Liposomes
have been used to encapsulate TPT, while free TPT was found to be less active against
subcutaneous xenografts of cancers than injection of nano-liposomal TPT.(Drummond,
2005;Tardi,2001) Liposomal encapsulation may improve the efficacy of TPT by increasing
increasing drug circulatory half-life and by providing the appropriate pH to maintain drug
activity.(Tardi, 2001;Burke, 1994) In either case, the effect may be an increased amount of active
drug present at the tumor site. In orthotopic, intracranial xenograft models of GBM, nanoli‐
posomal TPT demonstrated superior efficacy when administered directly into the tumor by
convection-enhanced delivery (CED).(Tardi, 2001;Saito,2006) CED of nano-liposomal TPT
increased TPT half-life in the brain vs free TPT, and conferred a highly significant survival
advantage. In a recent study, systemically administered nano-liposomal TPT had enhanced
efficacy in 3 orthotopic xenograft models of GBM.(Serwer,2011) Bioluminescence monitoring
of tumor growth and therapeutic response, survival benefit to animal subjects, and immune-
histochemical analysis of tumor apoptotic response to therapy were used to assess efficacy.
Although these results were promising, data from clinical trials would be more significant and
applicable to the demonstration of efficacy. Consistent with the inhibitor function, increased
DNA strand breaks in TPT-treated tumors, and an increase in activated caspase-3 (marker of
programmed cell death) were observed in this study.(Serwer,2011) Delivery of liposomal
packaged TPT to tumors increased both of these molecular events, leading to cell death.
Nano-liposomal topotecan (nLS-TPT) has anti-tumor activity when administered directly to
brain tumors by convection-enhanced delivery (CED).(Serwer,2011 poster) As a topoisomer‐
ase I inhibitor, topotecan (TPT) must be internalized in order to have a cytotoxic effect, hence
increasing cellular internalization may increase the anti-tumor activity of nLS-TPT. Attaching
an epidermal growth factor (EGFR)-specific antibody to the nLS-TPT surface increased EGFR-
targeting. EGFR activation is considered a proliferative event leading to more cell replication.
This receptor is commonly found on cell membranes in order to increase accessibility to ligand
binding, hence the antibody used for targeting in this study may increase specific binding to
cells that have increased expression of the receptor. Improved targeting rates of TPT-nLS
internalization in vitro, and secondly nLS-TPT-EGFR offered superior efficacy compared to
nLS-TPT in vivo.(Serwer,2011 poster) When coupled to the antibody, the internalization of the
inhibitor was highly and significantly increased as was the rate of internalization of nLS-TPT-
EGFR when compared to nLS-TPT in all cells that express EGFR. In vivo studies in both EGFR-
expressing mouse models of glioblastoma models showed a substantial dose dependent
benefit of nLS-TPT-EGFR treatment compared to nLS-TPT treatment.(Serwer, 2011 and poster)
The use of nLS-TPT-EGFR against glioblastomas that overexpress EGFR increases targeting
and improves internalization. This may ultimately increase survival by delaying tumor
growth.
The prognosis for newly-diagnosed GBM remains poor, and one of the reasons for this is that
GBM’s have the highest levels of vascular endothelial growth factor (VEGF) and hypoxia
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inducing factor-1 alpha (HIF-1 alpha), an important regulator of VEGF. Topotecan therapy
may play a role in this signalling pathway by inhibiting HIF-1 alpha in treated tumor cells,
limiting tumor vascularization. (Vredenburgh, 2011) A phase II trial in newly diagnosed GBM
added bevacizumab and topotecan to standard therapy. 80 newly diagnosed GBM patients
received standard radiation therapy and temozolomide with bevacizumab at 10 mg/kg every
14 days was added a minimum of 4 weeks post-op. Two weeks after radiation therapy was
completed, 12 monthly cycles of temozolomide, and oral topotecan were given for patients not
on an enzyme inducing anti-epileptic drug.(Vredenburgh, 2011) The addition of bevacizumab
to temozolomide and radiation followed by temozolomide, bevacizumab and oral topotecan
was tolerable and safe. Six patients came off the study with recurrent grade IV thrombocyto‐
penia, one each with grade 2 CNS hemorrhage, wound dehiscence requiring surgery and a GI
perforation. Median PFS and OS were not reached at a median follow-up of 8 months but the
6 month EFS was 83%. Hence in this case, multifactorial combination therapies for DNA
replication as well as vascularization may aid in treatment efficacy.
5. Irinotecan
Irinotecan is another water soluble topoisomerase inhibitor that is being used clinically for the
treatment of tumors. (Hsiang, 1985) A recent prospective, phase II study evaluated the efficacy
of irinotecan and bevacizumab in the treatment of recurrent glioblastoma multiforme (GBM).
(Møller,2012) In the evaluation of 85 patients with different brain tumors, the investigators
used response rate and progression free survival (PFS) in patients who received intravenous
bevacizumab (10 mg/kg), and irinotecan (125/340 mg/m2 ) every 14 days until progression. The
median treatment that these patients received was four cycles. At 8 week intervals, the patients
underwent MRI imaging and were evaluated based on the Macdonald response criteria. The
following histologies were studied among the 85 patients: GBM (n = 32), glioma WHO gr. III
(n = 33), glioma WHO gr. II (n = 12), others (n = 8). For glioblastoma, ORR (overall response
rate) was 25%, with 59% achieving stable disease. The median PFS in this study was 5.2 months.
Upon evaluating the other types of tumors, for grade III gliomas ORR was 21% and 45% had
SD with a median PFS of 3.7 months. Objective responses were not found for any grade II
gliomas in this study. (Møller,2012) Since the study included a non-glioma population, the
investigators reported that they observed several long PFS times. Bevacizumab and irinotecan
combination therapy was well tolerated and moderately efficacious in glioblastoma and
glioma of WHO grade III with the majority of patients achieving some disease stabilization.
(Møller, 2012) The current studies have evaluated irinotecan alone or in combination (ex:bev‐
acizumab). (Table 1) Future studies should expand on these findings in larger cohorts since
progression-free survival was prolonged in non-glioma patients.
6. Safety, adverse effects, and methods to minimize toxicity
Malignant gliomas are highly proliferative, resistant to therapy and often recurrent post
radiation and chemotherapy. Lack of adequately tumoricidal concentrations of chemothera‐
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peutic drugs in tumor cells may be be one of the primary causes of treatment failure in solid
tumors. The blood-brain barrier (BBB) restricts the concentrations of chemotherapeutic drugs
that may reach the tumor site. Methods that deliver drugs in a systemic fashion may increase
toxicity and create off target site complications. Convection-enhanced delivery (CED) is a
method that may provide drugs to the tumor in a more targeted fashion through the interstitial
space.(Barker,1998; Bobo,1994) This approach results into more drug being delivered into
tumors and surrounding brain through stereo-tactically placed catheters connected to pumps.
(Barker,1998; Bobo,1994) By providing a continuous, low grade positive-pressure microinfu‐
sion that distributes drugs by bulk flow, CED may result in high local concentrations and
reduce systemic toxicity. (Bruce,2011)
Topotecan, a topoisomerase I inhibitor, is cytotoxic to glioma cells and nontoxic to normal
brain, and its levels are higher in glioma cells and tumor tissue than in normal brain. Topotecan
is a natural-product drug with high molecular weight which allows it to minimally traverse
the BBB from the brain to the systemic circulation. (Kaiser,2000;Bruce,2000;Borris,1998,
Matsumoto, 1999) Now there is evidence that in colon tumors topotecan treatment results in
the downregulation of hypoxia-inducible factor-1α (HIF1A) target genes along with an
inhibition of HIF1A protein accumulation. (Guerin, 2012) Hence, topoisomerase I inhibitors
may also influence the tumor environment by decreasing tumor angiogenesis leading to tumor
size stabilization, although clinical trials of topotecan delivered intravenously had minimal
effects on tumors. (Fridman,1999) In other studies, CED in rat in vivo models prolonged
survival and had significant antitumor efficacy. (Kaiser,2000; Bruce,2000)
Recently, a prospective, dose-escalation phase Ib study of CED of topoisomerase-I was
conducted in sixteen patients with recurrent malignant gliomas with a median age of 50 years.
Ten patients had glioblastoma multiforme, and the other 6 had World Health Organization
grade III glial tumors with an average enhancing volume of 16.1 cm3. (Bruce,2011) Standard
MRI/CT-guided stereotactic biopsy was used to histologically confirm the presence of
recurrent malignant glioma. In this study, the investigators evaluated toxicity and quality of
life (QOL) effects and confirmed antitumor activity radiographically. The change in contrast-
enhancing volume of tumor on MRI was used to assess tumor response to treatment. Three
response categories were used to characterize the tumors: early response; as a decrease in
contrast-enhancing volume of >50% through the first 3 to 6 months after therapy, progressive
disease; as increasing contrast-enhancing volume (>25%) at ≥1 month after therapy until
surgical resection or death, and pseudoprogression; an increase in the contrast-enhancing
volume of >50% followed by regression of enhancement and edema (changes had to be
sustained for at least 4 weeks with patients on a stable or decreasing dose of steroids).(Bruce,
2011) The investigators noted significant antitumor activity in these tumors through radio‐
graphic changes, and treatment with CED topotecan prolonged overall survival. The maxi‐
mum tolerated dose that can be used for phase II studies was determined in this trial. Drug-
associated toxicity was minimal and topotecan convection-enhanced delivery had activity at
concentrations that were nontoxic to normal brain. (Bruce,2011)
CED locally administered topotecan treatment was tested on a rat model of glioblastoma that
is induced by intracerebral injection of PDGF (platelet-derived growth factor)-IRES (internal
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ribosome entry site) expressing retrovirus. (Lopez, 2011) Glial progenitor cells recruited to the
tumor and the transformed tumor cells were analyzed by histopathology. Glial progenitor cells
are proliferate within gliomas and contribute to the growth of the tumor. (Appolloni, 2009
OGDEN) This pro-growth process is influenced via PDGF signaling, another common
proliferative pathway. (Assanah, 2006 Assanah, 2009) The transformed cell population was
reduced about 10-fold and recruited progenitors by about 80-fold. A significant survival
advantage was found in treated animals and this improved with greater treatment duration.
(Lopez, 2011) In addition, the distribution of topotecan was traced with MRI of a tracer
molecule and corresponded with regions of glial progenitor ablation. The decrease in progen‐
itor recruitment was most likely due to the ablation of recruitable progenitor cells. These results
showed that in a model of growth factor influenced gliomas, tumor cells and the induced
progenitor cells are eradicated by topoisomerase inhibition based treatments. Hence, future
characterization of tumors through these methods may enhance the efficacy of treatments in
specific subpopulations. Topotecan administration by convection-enhanced delivery has
significant antitumor activity at concentrations that are nontoxic to normal brain. The potential
for use of this therapy as a generally effective treatment option for malignant gliomas will be
tested in subsequent phase II and III trials. (Bruce, 2011)
Topoisomerase II (epipodophyllotoxin) has been implicated in the pathogenesis of treatment-
related myelodysplastic syndrome/ treatment-related acute myelogenous leukemia (t-MDS/t-
AML). (Baehring, 2012) Once patients develop these t-MDS/t-AML disorders they are treated
with supportive care, including transfusion of blood products and administration of antibiot‐
ics; 5-azacytidine, decitabine, and lenalidomide are approved for the treatment of selected
patients with MDS in the United States. Hence, some of the side effects of topoisomerase
inhibition therapy for CNS tumors must be further investigated in additional head to head
clinical studies with other monotherapies or combinations that may alleviate adverse effects.
Additional ways to reduce or minimize toxicity include close monitoring of blood counts and
limiting long term usage of the drug.
7. Emerging topoisomerase therapies and combinations
Genz-644282 is a new a non-camptothecin topoisomerase I inhibitor (Kurtzberg, 2011) in
clinical  development.  Efficacy  for  this  novel  agent  was  tested  and  compared  with  the
standard anticancer drugs; irinotecan, docetaxel, and dacarbazine in human tumor xeno‐
grafts  of  colon cancer,  renal  cell  carcinoma,  non-small  cell  lung cancer,  and melanoma.
Genz-644282 had superior  or  equal  antitumor activity than the standard drug compara‐
tors, although brain tumor models were not utilized. (Kurtzberg) Genz-644282 and its me‐
tabolites induce Top1 cleavage at similar, as well as unique genomic positions, compared
with camptothecin which traps topoisomerase I (Top1)-DNA cleavage complexes. Protein-
linked DNA breaks are induced by Genz-644282,  and cleavage complexes persist  longer
after  compound  removal  than  camptothecin  treatment.  (Sooryakumar,  2011)  The  agent
was tested against the pediatric preclinical testing program (PPTP) panel as well as in vivo
using at its maximum tolerated dose (MTD) of 4 mg/kg (3 times per week × 2 schedule re‐
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peated at day 21).(Houghton, 2012) Testing was also conducted in model systems in or‐
der to determine a dose regulated response. Treatment exhibited potent cytotoxic activity
in vitro models, and in vivo it induced and maintained complete responses in all 6 solid
tumor  models  at  MTD.  At  lower  doses  of  2 mg/kg  it  induced  complete  responses  and
maintained  complete  responses  in  tumor  models  relatively  insensitive  to  Topotecan  al‐
though responses were not observed at lower doses. A significant correlation was found
between predictive response scores in baseline mRNA tumor gene expression profiles and
the observed in vivo responses to Genz-644282. Future research on clinical activity in chil‐
dren impacted by CNS tumors will depend on tolerated drug exposures and safety pro‐
files. (Houghton, 2012)
Topotecan has been studied in combination with other therapies that may increase treatment
efficacy in brain tumors. In a recent study, the combination of nanoliposomal topotecan (nLs-
TPT) and pegylated liposomal doxorubicin (PLD) was delivered with CED as treatment for
malignant brain tumors. (Yamashita, 2007) Both drugs decreased proteins and enzymes with
roles in cell replication in vitro, with some synergistic effects. Doxorubicin is also used to inhibit
topoisomerase II, and although these studies used implantation of tumor cells in animals, the
investigators conducted a survival study in which animals in the control group and the single
agent groups had a median survival that was less than the median survival of the combination
group. In this study combination therapy use two agents that were both encapsulated in
liposomes. Furthermore, the use of CED was promoted as an enhanced drug delivery method,
increasing drug availability at the brain tumor site and leading to tumor death.
New phase III randomized control trials incorporating the addition of bevacizumab for newly
diagnosed GBM patients may be informative and increase treatment efficacy. (Vredenburg,
2011) In combination with the use of specific molecular biomarkers, data from these trials may
clarify the role of anti-angiogenesis agents such as bevacizumab in combination therapy with
topoisomerase inhibitors. The incorporation of molecular signatures elicited by therapies such
as irinotecan will create a more descriptive situation of the tumor microenvironment, and lead
to the elucidation of additional therapeutic targets. (Guerin, 2012 )
Additional research into the use of low-dose etoposide (topoII inhibitor) with an oncolytic
herpes simplex virus increased survival of mice-bearing intracranial human GSC–derived
tumors. (Cheema) These results were found without adverse side effects, possibly leading to
this as an effective combination strategy to treat resistant and recurrent GBM in the future.
(Cheema)
In a recent study of both a neuroblastoma and astrocytoma cell line that were resistant to
chemotherapy  (eg.  temozolomide)  and  radiation  treatment,  investigators  found  that  a
novel cytotoxic compound was toxic to these these cells but not to human primary astro‐
cytes. This compound is an analog of thiobarbituric acid and is effective in subcutaneous
and intracranial mouse tumor models with a good safety profile. (Lee, 2011) The mecha‐
nism of  action of  the lead compound has topoisomerase IIa  inhibition activity but  does
not inhibit topoisomerase I activity. These types of studies may lead to the development
of new agents that can overcome some of the tumor resistance mechanisms in temozolo‐
mide and radiation resistant astrocytomas.
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8. Predictive biomarkers and tests
The development of molecular markers which predict response to chemotherapy is an
important aspect of current neuro-oncology research. The studies and subsequent tests that
may assess the status of these biomarkers are ongoing, but few molecules are being tested at
this time. O 6-methylguanine-DNA methyltransferase MGMT promoter methylation is the
only proved marker of glioblastoma. (Weller,2010) This DNA repair enzyme antagonizes the
genotoxic effects of alkylating agents. The expression of MGMT in tumor cells is a marker for
significant resistance to temozolomide therapy and other treatments. (Liu, 2006; Donson,
2007; Hegi, 2005) MGMT promoter methylation is the key mechanism of MGMT gene silencing
and predicts a favorable outcome in patients with glioblastoma who are exposed to alkylating
agent chemotherapy. (Weller,2010) The predictive or prognostic value of MGMT promoter
methylation may differ depending on glioma subtypes, and the extent to which testing should
be incorporated into routine clinical practice is still under investigation.
A recent study assessed the effect of topoisomerase expression on glioblastoma survival and
the mechanisms involved. (Arivazhagan,2012) In an effort to correlate outcome with gene
expression, the transcript levels of all isoforms of the topoisomerase family in all grades of
diffuse astrocytoma were assessed in this prospective study of patients with glioblastoma
treated by a uniform treatment procedure. Transcript levels of TOP2A, TOP2B, and TOP3A
were up regulated significantly in GBM in comparison with lower grades of astrocytoma and
normal brain samples. The mRNA levels of TOP2A correlated significantly with survival of
the patients, and better prognosis in GBM patients. Temozolomide (Arivazhagan,2012) was
also a TOP2A inhibitor, and TOP2A transcript levels determined the chemosensitivity of
glioblastoma to temozolomide therapy. Very high levels of TOP2A were considered a good
prognostic indicator in GBM patients receiving temozolomide chemotherapy. Methylation of
the MGMT promoter was found to be the strongest predictor of outcome and benefit from
temozolomide chemotherapy. (Stupp,2009) Analysis of progression free survival revealed an
advantage solely for patients whose tumor had a methylated MGMT promoter and who were
treated with temozolomide and radiotherapy. Hence, in this patient analysis relied on
combination therapy was as opposed to monotherapy. These types of results may serve as the
impetus for the identification of new genetic biomarkers for GBM and the development of
therapies targeting new molecular targets.
9. Conclusions
The treatment of primary malignancies of the CNS continues to be a challenging problem since
their treatment is complicated due to anatomical site and the intricacy of the blood brain
barrier. Topoisomerase I (topo I) inhibitors, in addition to temozolomide and nitrosourea
compounds, represent one promising one treatment option. While preclinical studies in glioma
models were promising, clinical trials with topo I inhibitors with topotecan and CPT-11
showed only modest benefit in phase II clinical trials. Children with anaplastic astrocytoma
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or glioblastoma (Turner, 2002) appear to benefit more with higher response rates than adults
with the same tumors. (Friedman,1999; Batchelor, 2004)
The combination of topo I inhibitors with drugs that block angiogenesis including VEGF
appear promising, and further studies are needed in the establishment of efficacy, and the
development of treatment strategy. However, serious toxicity such as CNS hemorrhage and
leukoencephalopathy may occur with these agents. (Ozcan,2006) Further clinical trials are
needed to better define the patients at risk for these major side effects.
Another future approach is combining topo I inhibitors together with targeted agents and
antiangiogenesis drugs. For example, NF-қB activation in glioma cells may be induced by
campothecins leading to inhibition of apoptosis in these cells. It has been shown that over‐
production of IL-1Β can sustain NF-қB activation (Morandi,2006) and agents that inhibit NF-
қB activation may increase the susceptibility of glioma cells y to apoptosis induced by
campothecin. (Weaver,2003)
Other agents that may increase the efficacy of topo I drugs include the new chemotherapy
drug, irofulven. (Woo,2005) PKC inhibitors in combination with CPT-11 have also shown
promise in laboratory studies. (Chen TC, 2003) These studies demonstrated an increase in
apoptosis and decrease in proliferation in glioma cell lines when exposed to both agents. A
decrease in the antiapoptotic protein bcl-2 and an increase in the proapoptotic bax protein may
be propagate this mechanism of apoptosis.
Other novel approaches include the use of agents to increase penetration of topotecan into
glioma cells. (Carcaboso, 2010) It is possible that one mechanism of drug resistance to topotecan
is increased pumping of drug out of the cell. It is known that topotecan is a substrate of the
ATP-binding cassette (ABC) transporters P-glycoprotein and breast cancer resistance protein
(BCRP/ABCG2). In mice it has been shown that the epidermal growth factor receptor tyrosine
kinase inhibitor, Gefitinib, can increase intracellular drug penetration into glioma cells. Similar
approaches in the treatment of brain tumors may increase drug availability to the tumor
environment.
Immunotherapy for treatment of malignant gliomas has usually been unsuccessful. One new
approach is to add topotecan to enhance immune clearance of gliomas. (Wei J,2009) Preclinical
studies with the human glioma cell line U-87 using topotecan showed that the drug can
upregulate functional Fas receptors and the resulting upregulated Fas expression can increase
susceptibility to cytotoxic T cell killing. These findings will have to be substantiated through
additional clinical studies and testing.
Another novel approach is to increase drug delivery across the blood brain barrier. Liposomes
incorporating Tamoxifen and wheat germ agglutinin have improved the transport of topote‐
can across the blood brain barrier in brain tumor-bearing rats. (Du 2009) In these studies,
improved survival may be related to the enhanced effect of Tamoxifen by inhibiting efflux of
multidrug resistant proteins in the blood brain barrier and/or an enhanced effect by the wheat
germ agglutinin via endocytosis in the blood brain barrier and in the brain tumor.
Another method to deliver more drug into brain tumors is by a convection-delivery system.
This approach may be advantageous by potentially increasing drug delivery into the brain
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tumor while reducing systemic side effects. Regression of malignant gliomas by this convec‐
tion-enhanced delivery system has been reported recently. (Bruce, 2011) Future phase II trials
are being planned with this technique since the maximum tolerated dose has been established.
Finally, there are newer generations of topo I inhibitors being evaluated and several have
entered into clinical trials in human patients. These newer topo I inhibitors include Diflomo‐
tecan, Karenitecin, Silatecan, PEG-camptothecin, Rubitecan, 9-aminocamptothecin, Exatecan
mesylate, Lurtotecan, and Gimatecan. (Pommier, 2006) A phase II trial of Rubitecan in patients
with glioblastoma showed disappointing results. (Raymond,2002) A phase I and pharmaco‐
kinetic study of Karenitecin in patients with recurrent malignant gliomas was recently
reported. (Grossman, 2008)
Since the vast majority of patients with malignant gliomas die of their disease, it is clear that
newer and more effective drugs are needed. There has been renewed interest in topoisomerase
I inhibitors in brain tumors using innovative drug carriers or drug delivery systems. In
addition, novel topoisomerase I inhibitors are promising and are currently being explored and
investigated.
Investigator n Treatment Response Rate Ref.
Møller et al. 85 IV bevacizumab (10 mg/kg),
irinotecan (125/340 mg/m2 ) every
14d until progression
ORR (overall response rate) was
25%, with 59% achieving stable
disease; median PFS of 5.2 months
Møller, 2012
Bruce et al. 16 Dose escalation of Ib study of CED of
topotecan
Significant antitumor activity by
radiographic changes, and




80 Add. bevacizumab to temozolomide
and radiation followed by temozolo-
mide, bevacizumab, topotecan
Median PFS and OS not reached at a
median follow-up of 8 months but





25 After combined treatment with
bevacizumab and
itinotecandetermine the
independent prognostic value of
(FDG)-PET on PFS and OS of recurrent
histologically proven high grade
glioma, compared with other
documented prognostic variables.
Imaging was performed within 6
weeks of starting chemotherapy
Median PFS and OS were 4 months
(range, 0.9-10.4 months) and 7.2
months (range, 1.2-41.7 months),
respectively. At 6 months, PFS and
OS rate were 16.0% and 72.0%.
FDG uptake was the most powerful
predictor of both PFS and OS
Colavolpe,
2012
Paldino et al. 15 Determine the prognostic
significance of changes in parameters
derived from diffusion tensor
imaging (DTI) that occur in response
to treatment with bevacizumab and
DTI detected a change in Apparent
diffusion coefficient (ADC) within
FLAIR signal abnormality (FSA).
Patients with a change in ADC
within FSA had significantly shorter
Paldino, 2012
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Investigator n Treatment Response Rate Ref.
irinotecan in patients with recurrent
GM through serial 1.5 T MRI. Axial
single-shot echo planar DTI was
obtained on scans performed 3 days
and 1 day prior to and 6 wks. after
initiation of therapy.
overall survival (p=0.032) and
progression free survival (p=0.046)
than those with no change.
Desjardins et
al.
32 PII trial of combined protracted daily
temozolomide 50 mg/m(2) and
biweekly bevacizumab (10mg/kg) IV
for patients with recurrent
glioblastoma who had previously
received radiation therapy and
temozolomide. Underwent physical
examination and brain MRI every 8
weeks.
6month PFS rate 18.8% (95% [CI],
7.6%-33.7%), median PFS 15.8 wks.
Median OS of 37 wks.,6-m OS rate
of 62.5% (95% CI, 43.5%-76.7%),
12-m OS rate of 31.3% (95% CI,
16.4%-47.3%). Patients progressed;
locally (52%), diffuse pattern (38%),
distant (10%). Regimen had some
activity and was well tolerated but
results obtained were inferior to
those observed in studies of
bevacizumab monotherapy and of
combination with irinotecan.
Patient population was more
heterogeneous and pretreated






40 Phase II, open, label, single arm trial




carboplatin (area under the plasma
curve [AUC] 4 mg/ml-min) on day
one, while bevacizumab (10 mg/kg)
and irinotecan (340 mg/m(2) for
patients on CYP3A-enzyme-inducing
anti-epileptics [EIAEDs] and 125 mg/
m(2) for patients not on EIAEDs)
administered on days 1 and 14 of
every 28-day cycle. Evaluated after
each of the first 2 cycles and then
after every other cycle. Treatment
continued until progressive disease,
unacceptable toxicity, non-
compliance, or voluntary withdrawal.
All patients had progression after
standard therapy, patients (40%)
had a KPS of 90-100, while 68%
were at first progression. PFS-6 rate
was 46.5% (95% CI: 30.4, 61.0%)
and median OS of 8.3 months [95%
CI: 5.9, and 10.7 months]. Addition
of carboplatin and irinotecan to
bevacizumab significantly increases
toxicity but does not improve anti-
tumor activity to that achieved
historically with single-agent
bevacizumab among bevacizumab-
naïve, recurrent GBM patients.
Reardon, 2012
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Investigator n Treatment Response Rate Ref.
Reardon, et
al.
Phase II, open, label, single arm trial
on efficacy of carboplatin, irinotecan,
and bevacizumab among recurrent
glioblastoma (GBM) patients after
prior progression on bevacizumab
therapy. Received carboplatin (area
under the plasma curve [AUC] 4
mg/ml-min) on day 1, bevacizumab
(10 mg/kg) and irinotecan (340 mg/
m(2) for patients on CYP3A enzyme-
inducing anti-epileptics [EIAEDs] and
125 mg/m(2) for patients not on
EIAEDs) were administered on days 1
and 14 of every 28-day cycle. Patients
were evaluated after each of the first
2 cycles and then after every other
cycle. Treatment continued until
progressive disease, unacceptable
toxicity, noncompliance, or voluntary
withdrawal.
All patients had progression on at
least 1 prior bevacizumab regimen
and 56% enrolled after either 2nd or
3rd overall progression. Median OS
was 5.8 months (95% [CI], 4.0-7.0
months) and PFS-6 rate was 16%
(95% CI, 5.0%-32.5%). Carboplatin,
irinotecan, and bevacizumab was
associated with modest activity and
adequate safety among these
patients.
Reardon, 2011
Parekh et al. 8 Retrospectively reviewed the records
of patients <21 yrs. of age with
recurrent or progressive WHO grade
3-4 gliomas who were treated with




bevacizumab, one patient received
irinotecan and bevacizumab, and one
patient received CCNU and
bevacizumab.
3 patients had stable disease for
30-93 weeks, 5 patients progressed
within 17 wks., median PFS was 15
weeks, 6-m PFS was 38%. Contrast
enhancing disease responded or
remained stable in 5/7 patients, and
non-enhancing disease progressed
in 3/4 patients. Bevacizumab was
well tolerated when used in
combination with conventional
chemotherapy (irinotecan in most
cases). PFS in cohort was much
shorter and the response rate was
inferior in this small cohort of
patients when compared with
published adult data, but
bevacizumab regimens may have




Pope et al. 85 Evaluated patterns of tumor
progression in patients with recurrent
79% treated with single-agent BEV
and 70% of patients treated with
Pope, 2011
Topoisomerase Therapy in the Treatment of Brain Tumors
http://dx.doi.org/10.5772/53184
451
Investigator n Treatment Response Rate Ref.
glioblastoma who were treated with
bevacizumab (BEV) alone or in
combination with irinotecan (CPT-11)
while participating in the BRAIN
study. Iindependent neuroradiologist
reviewed MRI scans in patients who
received BEV or BEV+CPT-11 while on
BRAIN. 28% of patients who
participated had nonlocal disease at
baseline.
BEV+CPT-11 experienced disease
progression while on BRAIN. Most
patients did not have a change in
radiographic pattern (i.e., "no shift")
at the time of progression. 82% of
BEV patients had no shift and BEV
+CPT-11 patients (53%, χ(2) p =
0.0004), and a greater proportion of
BEV+CPT-11 (39%) compared with
BEV (16%) experienced local-to-
diffuse tumor pattern at
progression (χ(2) p = 0.002).
Patients treated with BEV or BEV
+CPT-11 who had local-to-local or
local-to-diffuse progression patterns
had similar efficacy outcomes,
including objective response, PFS,
and OS.
Table 1. Recent studies of topoisomerase inhibitors as monotherapies or in combination with other
chemotherapeutics for the treatment of brain tumors
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